FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897744768> ?p ?o ?g. }

• W2897744768 endingPage "18" @default.
• W2897744768 startingPage "14" @default.
• W2897744768 abstract "Despite advances in pharmacotherapy, diabetic kidney disease (DKD) remains associated with a high burden of micro‐ and macrovascular complications often leading to premature mortality. New therapies are highly desirable to mitigate the burden of this disease. However, there are a number of barriers that hamper drug development in DKD. These include, amongst others, the lengthy and complex clinical trials required to prove drug efficacy and safety, inefficiencies in clinical trial conduct, and the high costs associated with these development programs. In this review a number of aspects are discussed, aiming to identify opportunities to transform and innovate drug development for DKD. Many clinical trials in DKD, as well as in other areas, face difficulties in timely and efficient enrolment of participants. To address this issue a network of sites should be created that are continuously recruiting individuals with DKD and collecting crucial information that can be used to understand prognosis and prognostic factors, and more importantly to serve as a pool of participants for recruitment to randomized trials. Second, the current clinical endpoints are late events in the progression of DKD. Endpoints based on lesser declines in estimated glomerular filtration rate (eGFR) or changes in albuminuria can shorten follow‐up and/or lead to smaller and cheaper trials. Enrichment by enrolling clinical trial populations based on biomarker profiles is another approach that may facilitate clinical trial efficiency and conduct. Biomarkers can be used to individualize treatment by targeting populations more likely to respond leading to smaller and more efficient trials. Finally, using new trial design such as basket, umbrella or more broadly platform trials to assess a number of therapies simultaneously offers the potential to transform the drug development process in DKD. There are a number of opportunities to transform development approaches for new therapies for DKD. Platform trials along with appropriate biomarker‐based enrichment strategies offer the possibility to foster drug development in a precision medicine era." @default.
• W2897744768 created "2018-10-26" @default.
• W2897744768 creator A5027520502 @default.
• W2897744768 creator A5059176189 @default.
• W2897744768 creator A5062276281 @default.
• W2897744768 date "2018-10-01" @default.
• W2897744768 modified "2023-10-02" @default.
• W2897744768 title "New clinical trial designs for establishing drug efficacy and safety in a precision medicine era" @default.
• W2897744768 cites W2044674895 @default.
• W2897744768 cites W2054837618 @default.
• W2897744768 cites W2101462230 @default.
• W2897744768 cites W2115034481 @default.
• W2897744768 cites W2133169646 @default.
• W2897744768 cites W2134120087 @default.
• W2897744768 cites W2152096085 @default.
• W2897744768 cites W2152798629 @default.
• W2897744768 cites W2157677292 @default.
• W2897744768 cites W2161821474 @default.
• W2897744768 cites W2394782024 @default.
• W2897744768 cites W2471493685 @default.
• W2897744768 cites W2552060437 @default.
• W2897744768 cites W2584526957 @default.
• W2897744768 cites W2611937140 @default.
• W2897744768 cites W2626446274 @default.
• W2897744768 cites W2726405642 @default.
• W2897744768 cites W2741457765 @default.
• W2897744768 cites W2791011305 @default.
• W2897744768 cites W2793672077 @default.
• W2897744768 cites W2795033409 @default.
• W2897744768 cites W2802682852 @default.
• W2897744768 doi "https://doi.org/10.1111/dom.13417" @default.
• W2897744768 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6220936" @default.
• W2897744768 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30294954" @default.
• W2897744768 hasPublicationYear "2018" @default.
• W2897744768 type Work @default.
• W2897744768 sameAs 2897744768 @default.
• W2897744768 citedByCount "16" @default.
• W2897744768 countsByYear W28977447682018 @default.
• W2897744768 countsByYear W28977447682019 @default.
• W2897744768 countsByYear W28977447682020 @default.
• W2897744768 countsByYear W28977447682021 @default.
• W2897744768 countsByYear W28977447682022 @default.
• W2897744768 countsByYear W28977447682023 @default.
• W2897744768 crossrefType "journal-article" @default.
• W2897744768 hasAuthorship W2897744768A5027520502 @default.
• W2897744768 hasAuthorship W2897744768A5059176189 @default.
• W2897744768 hasAuthorship W2897744768A5062276281 @default.
• W2897744768 hasBestOaLocation W28977447681 @default.
• W2897744768 hasConcept C126322002 @default.
• W2897744768 hasConcept C141341695 @default.
• W2897744768 hasConcept C142724271 @default.
• W2897744768 hasConcept C148482608 @default.
• W2897744768 hasConcept C149172746 @default.
• W2897744768 hasConcept C163763905 @default.
• W2897744768 hasConcept C168563851 @default.
• W2897744768 hasConcept C177713679 @default.
• W2897744768 hasConcept C185592680 @default.
• W2897744768 hasConcept C2779134260 @default.
• W2897744768 hasConcept C2780035454 @default.
• W2897744768 hasConcept C2781197716 @default.
• W2897744768 hasConcept C502991105 @default.
• W2897744768 hasConcept C535046627 @default.
• W2897744768 hasConcept C55493867 @default.
• W2897744768 hasConcept C64903051 @default.
• W2897744768 hasConcept C71924100 @default.
• W2897744768 hasConcept C98274493 @default.
• W2897744768 hasConceptScore W2897744768C126322002 @default.
• W2897744768 hasConceptScore W2897744768C141341695 @default.
• W2897744768 hasConceptScore W2897744768C142724271 @default.
• W2897744768 hasConceptScore W2897744768C148482608 @default.
• W2897744768 hasConceptScore W2897744768C149172746 @default.
• W2897744768 hasConceptScore W2897744768C163763905 @default.
• W2897744768 hasConceptScore W2897744768C168563851 @default.
• W2897744768 hasConceptScore W2897744768C177713679 @default.
• W2897744768 hasConceptScore W2897744768C185592680 @default.
• W2897744768 hasConceptScore W2897744768C2779134260 @default.
• W2897744768 hasConceptScore W2897744768C2780035454 @default.
• W2897744768 hasConceptScore W2897744768C2781197716 @default.
• W2897744768 hasConceptScore W2897744768C502991105 @default.
• W2897744768 hasConceptScore W2897744768C535046627 @default.
• W2897744768 hasConceptScore W2897744768C55493867 @default.
• W2897744768 hasConceptScore W2897744768C64903051 @default.
• W2897744768 hasConceptScore W2897744768C71924100 @default.
• W2897744768 hasConceptScore W2897744768C98274493 @default.
• W2897744768 hasFunder F4320314178 @default.
• W2897744768 hasFunder F4320321800 @default.
• W2897744768 hasIssue "S3" @default.
• W2897744768 hasLocation W28977447681 @default.
• W2897744768 hasLocation W28977447682 @default.
• W2897744768 hasLocation W28977447683 @default.
• W2897744768 hasLocation W28977447684 @default.
• W2897744768 hasLocation W28977447685 @default.
• W2897744768 hasOpenAccess W2897744768 @default.
• W2897744768 hasPrimaryLocation W28977447681 @default.
• W2897744768 hasRelatedWork W1680941824 @default.
• W2897744768 hasRelatedWork W2009224795 @default.
• W2897744768 hasRelatedWork W2065271792 @default.
• W2897744768 hasRelatedWork W2114281628 @default.

• next